TY - JOUR
T1 - Efficacy of 7 day lansoprazole-based triple therapy for Helicobacter pylori infection in elderly patients
AU - Pilotto, Alberto
AU - Franceschi, Marilisa
AU - Leandro, Gioacchino
AU - Bozzola, Loredana
AU - Fortunato, Antonio
AU - Rassu, Mario
AU - Meli, Salvatore
AU - Soffiati, Giuliano
AU - Scagnelli, Mariuccia
AU - Di Mario, Francesco
AU - Valerio, Gianni
PY - 1999
Y1 - 1999
N2 - Background: The prevalence of Helicobacter pylori increases with age. However, data regarding the effects of anti-H. pylori treatments in the elderly are very scarce. Methods: To evaluate the effect of three lansoprazole-based, 7 day, triple-therapy regimens on H. pylori eradication rates, symptomatology, chronic gastritis activity and serological markers of H. pylori infection in elderly subjects, we studied 150 symptomatic patients over 60 years of age with H. pylori-positive duodenal ulcer (DU, n = 34), gastric ulcer (GU, n = 19) or chronic gastritis (CG, n = 97). Patients were consecutively treated with one of the following regimens: (A) lansoprazole (LNS) 30 mg b.i.d. + clarithromycin (CLR) 250 mg b.i.d.+ metronidazole (MTR) 250 mg q.i.d.; (B) LNS 30 mg b.i.d. + amoxycillin (AMOX) 1 g b.i.d. + MTR 250 mg q.i.d.; and (C) LNS 30 mg b.i.d. + CLR 250 mg b.i.d. + AMOX 1 g b.i.d. Results: Two months after therapy, the eradication rates of the three treatments, expressed using both intention-to-treat and per-protocol analyses were, respectively; group A, 86 and 91.5%; group B, 80 and 87%; group C, 82 and 89.1%. After therapy, a significant reduction in epigastric pain (P <0.001), heartburn (P=0.02), dyspepsia (P<0.001) and vomiting (P
AB - Background: The prevalence of Helicobacter pylori increases with age. However, data regarding the effects of anti-H. pylori treatments in the elderly are very scarce. Methods: To evaluate the effect of three lansoprazole-based, 7 day, triple-therapy regimens on H. pylori eradication rates, symptomatology, chronic gastritis activity and serological markers of H. pylori infection in elderly subjects, we studied 150 symptomatic patients over 60 years of age with H. pylori-positive duodenal ulcer (DU, n = 34), gastric ulcer (GU, n = 19) or chronic gastritis (CG, n = 97). Patients were consecutively treated with one of the following regimens: (A) lansoprazole (LNS) 30 mg b.i.d. + clarithromycin (CLR) 250 mg b.i.d.+ metronidazole (MTR) 250 mg q.i.d.; (B) LNS 30 mg b.i.d. + amoxycillin (AMOX) 1 g b.i.d. + MTR 250 mg q.i.d.; and (C) LNS 30 mg b.i.d. + CLR 250 mg b.i.d. + AMOX 1 g b.i.d. Results: Two months after therapy, the eradication rates of the three treatments, expressed using both intention-to-treat and per-protocol analyses were, respectively; group A, 86 and 91.5%; group B, 80 and 87%; group C, 82 and 89.1%. After therapy, a significant reduction in epigastric pain (P <0.001), heartburn (P=0.02), dyspepsia (P<0.001) and vomiting (P
KW - Amoxycillin
KW - Chronic gastritis
KW - Clarithromycin
KW - Elderly
KW - Helicobacter pylori infection
KW - Lansoprazole
KW - Metronidazole
KW - Peptic ulcer
KW - Therapy
UR - http://www.scopus.com/inward/record.url?scp=0032989526&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0032989526&partnerID=8YFLogxK
U2 - 10.1046/j.1440-1746.1999.01893.x
DO - 10.1046/j.1440-1746.1999.01893.x
M3 - Article
C2 - 10355512
AN - SCOPUS:0032989526
VL - 14
SP - 468
EP - 475
JO - Journal of Gastroenterology and Hepatology (Australia)
JF - Journal of Gastroenterology and Hepatology (Australia)
SN - 0815-9319
IS - 5
ER -